首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   15840篇
  免费   925篇
  国内免费   291篇
耳鼻咽喉   34篇
儿科学   517篇
妇产科学   135篇
基础医学   2360篇
口腔科学   103篇
临床医学   789篇
内科学   1968篇
皮肤病学   100篇
神经病学   90篇
特种医学   92篇
外国民族医学   1篇
外科学   371篇
综合类   1440篇
一般理论   2篇
预防医学   7108篇
眼科学   26篇
药学   1168篇
  4篇
中国医学   71篇
肿瘤学   677篇
  2024年   3篇
  2023年   507篇
  2022年   591篇
  2021年   715篇
  2020年   721篇
  2019年   629篇
  2018年   665篇
  2017年   582篇
  2016年   582篇
  2015年   689篇
  2014年   884篇
  2013年   1246篇
  2012年   961篇
  2011年   1083篇
  2010年   880篇
  2009年   832篇
  2008年   504篇
  2007年   693篇
  2006年   593篇
  2005年   513篇
  2004年   481篇
  2003年   426篇
  2002年   321篇
  2001年   299篇
  2000年   246篇
  1999年   230篇
  1998年   155篇
  1997年   156篇
  1996年   109篇
  1995年   84篇
  1994年   73篇
  1993年   71篇
  1992年   50篇
  1991年   56篇
  1990年   58篇
  1989年   63篇
  1988年   50篇
  1987年   40篇
  1986年   41篇
  1985年   60篇
  1984年   27篇
  1983年   15篇
  1982年   20篇
  1981年   15篇
  1980年   8篇
  1979年   6篇
  1978年   11篇
  1977年   3篇
  1976年   2篇
  1974年   3篇
排序方式: 共有10000条查询结果,搜索用时 125 毫秒
1.
[摘要] 目的 探讨上海某方舱医院新型冠状病毒奥密克戎变异株感染者的发病情况及流行病学特征。方法 以2022年4月9日—5月5日上海国家会展中心方舱医院收治的新型冠状病毒奥密克戎变异株感染者为研究对象,对感染者年龄、性别、地区、疫苗接种等疫情数据进行流行病学特征分析。结果 122 151例新型冠状病毒感染者均为奥密克戎变异株BA.2或BA.2.2亚型感染,其流行病学特征结果显示:患者男女比例为1.51:1;平均年龄为(44.91±15.38)岁;0~17岁、18~30岁、31~60岁和≥61岁感染者分别占4.74%、20.80%、62.52%和11.94%;无症状感染者占80.80%,轻型患者占19.20%;平均住院时间为(7.00±2.77)d;未接种和完成1、2和3次疫苗接种的感染者分别占20.30%、3.18%、31.30%和45.22%,其中≥61岁且完成3次疫苗接种的感染者仅占10.10%。结论 各个年龄段人群对于新型冠状病毒奥密克戎变异株普遍易感。无症状感染者是本次疫情的主体人群,临床症状不典型,早期隐匿传播,积极加强核酸检测是早期发现疫情的必要手段。  相似文献   
2.
《Vaccine》2022,40(27):3721-3726
We initiated a randomized, placebo-controlled, phase 1/2 trial to evaluate the safety and immunogenicity of the S-268019-b recombinant protein vaccine, scheduled as 2 intramuscular injections given 21 days apart, in 60 randomized healthy Japanese adults. We evaluated 2 regimens of the S-910823 antigen (5 μg [n = 24] and 10 μg [n = 24]) with an oil-in-water emulsion formulation and compared against placebo (n = 12). Reactogenicity was mild in most participants. No serious adverse events were noted. For both regimens, vaccination resulted in robust IgG and neutralizing antibody production at days 36 and 50 and predominant T-helper 1-mediated immune reaction, as evident through antigen-specific polyfunctional CD4+ T-cell responses with IFN-γ, IL-2, and IL-4 production on spike protein peptides stimulation. Based on the interim analysis, the S-268019-b vaccine is safe, produces neutralizing antibodies titer comparable with that in convalescent serum from COVID-19-recovered patients. However, further evaluation of the vaccine in a large clinical trial is warranted.  相似文献   
3.
A number of pneumococcal carriage studies in children have been conducted in recent years. However, summary data of carriage prevalence and serotype distribution from South East Asia Region (SEAR) are limited. This may lead to the misconception that Streptococcus pneumoniae vaccine-types are uncommon in the region. Systematic reviews of pneumococcal carriage and the distribution of serotypes are critically important for evidence-based decision-making. We aimed to summarize published data on the serotype prevalence of S. pneumoniae carried in the nasopharynx of children under 5 years of age in SEAR. We performed a systematic review and meta-analysis for relevant studies on S. pneumoniae carriage conducted prior to PCV program implementation from online journal databases published between January 2001 to December 2019. The pooled prevalence of S. pneumoniae in healthy children under 5 years of age in SEAR was 36.0% (95% CI 34.2%–37.8%), and ranged from 68.0% (95% CI: 61.9%–74.0%) in Cambodia to 7.6% (95% CI: 5.7%–9.6%) in Malaysia. Serotypes 6A/B, 23F and 19F were the most common serotypes in children <5 years, accounting for 12.9% (95% CI: 9.4%–16.3%), 9.3% (95% CI: 5.9%–12.8%) and 10.1% (95% CI: 6.6%–13.5%) of isolates, respectively. Vaccine policy makers should take these results into account when making decisions on pneumococcal conjugate vaccine programs implementation. Given the paucity of data, collection of more extensive and updated information of S. pneumoniae serotype epidemiology in children under five years in SEAR is also very important for future studies.  相似文献   
4.
《Value in health》2022,25(8):1290-1297
ObjectivesThe COVID-19 pandemic forms an unprecedented public health, economic, and social crisis. Uptake of vaccination is critical for controlling the pandemic. Nevertheless, vaccination hesitancy is considerable, requiring policies to promote uptake. We investigate Dutch citizens’ preferences for policies that aim to promote vaccination through facilitating choice of vaccination, profiling it as the norm, making vaccination more attractive through rewards, or punishing people who reject vaccination.MethodsWe conducted a discrete choice experiment in which 747 respondents were asked to choose between policies to promote vaccination uptake and their impacts on the number of deaths, people with permanent health problems, households with income loss, and a tax increase.ResultsRespondents generally had a negative preference for policies that promote vaccination. They particularly disliked policies that punish those who reject the vaccine and were more favorable toward policies that reward vaccination, such as awarding additional rights to vaccinated individuals through vaccination passports. Respondents who reject vaccination were in general much more negative about the policy options than respondents who consider accepting the vaccine. Nevertheless, vaccination passports are supported by both respondents who accept the vaccine, those who reject vaccination, and those who are unsure about vaccination.ConclusionsThis study provides concrete directions for governments attempting to increase the vaccination uptake in ways that are supported by the public. Our results could encourage policy makers to focus on policy options that make vaccination easier and reward people who take the vaccine, as especially the implementation of vaccination passports was supported.  相似文献   
5.
《Vaccine》2022,40(30):4038-4045
PurposeAs protection from COVID-19 following two doses of the BNT162b2 vaccine showed a time dependent waning, a third (booster) dose was administrated. This study aims to compare the antibody response following the third dose versus the second and to evaluate post-booster seroconversion.MethodsA prospective observational study conducted in Maccabi Healthcare Services. Serial SARS-CoV-2 Spike IgG tests, 1,2,3 and 6 months following the second vaccine dose and one month following the third were obtained. Neutralizing antibody levels were measured in a subset of participants. Per individual SARS-CoV-2 Spike IgG titer ratios were calculated one month after the booster administration compared to titers one month following the second dose and prior to booster.ResultsAmong 110 participants, 56 (51%) were women. Mean age was 61.7 ± 1.9 years and 66 (60%) were immunocompromised. One month after third dose, IgG titers were induced 7.83 (95 %CI 5.25–11.67) folds and 2.40 (95 %CI 1.90–3.03) folds compared to one month after the second, in the immunocompromised and immunocompetent groups, respectively. Of the 17 immunocompromised participants who were seronegative after the second dose, 4 (24%) became seropositive following the third. Comparing the titers prior to the third dose, an increase of 50.7 (95 %CI 32.5–79.1) fold in the immunocompromised group and 25.7 (95 %CI 19.1–34.7) fold in and immunocompetent group, was observed.ConclusionA third BNT162b2 vaccine elicited robust humoral response, superior to the response observed following the second, among immunocompetent and immunocompromised individuals.  相似文献   
6.
目的 对感染性腹泻样本进行检测鉴定,并对轮状病毒A组进行病毒分离,研究2019年广东省部分地区感染性腹泻病原学及轮状病毒分子流行病学特征。方法 2019年1月1日至2020年1月12日,采集广东省广州市、东莞市和江门市临床感染性腹泻患者粪便样本,进行多重RT-PCR扩增和微球杂交技术检测鉴定,并对轮状病毒A组阳性样本进行分离后,采用半巢式PCR试验对阳性细胞培养物进行G/P基因分型。结果 共纳入706例合格病例,病原体总检出率43.06%,病毒检出率18.13%高于细菌检出率8.36%高于寄生虫检出率1.27%。病毒病原谱以轮状病毒A组G9P[8]和诺如病毒GII型感染为主,细菌病原谱以沙门菌和艰难梭菌为主,寄生虫以蓝氏贾第鞭毛虫为首。不同季度、不同年龄组病原谱构成各不相同。轮状病毒A组主要受累群体为≤5岁儿童,主要时间分布于1—4月,基因型呈现多样性,包括G2P[4]、G3P[8]和G9P[8]。结论 2019年广东省部分地区感染性腹泻病毒类病原体高于细菌类高于寄生虫类,轮状病毒A组G9P[8]、诺如GII型、沙门菌和蓝氏贾第鞭毛虫是最主要的病原体,且G9P[8]型A组轮状病毒毒株在轮状病毒感染中占主导趋势。在防控病毒性和细菌性腹泻的同时,应警惕寄生虫所致腹泻并重视混合感染的病原学监测。  相似文献   
7.
《Molecular therapy》2022,30(5):1885-1896
  1. Download : Download high-res image (90KB)
  2. Download : Download full-size image
  相似文献   
8.
ObjectiveCoronavirus disease 2019 (COVID-19) vaccine mandates are being implemented in health systems across the United States, and the impact on the radiology department workforce and operations becuase of vaccine hesitancy among health care workers is currently unknown. This article discusses the potential impact of the COVID-19 vaccine mandate on a large multicenter radiology department as well as strategies to mitigate those effects.MethodsWeekly vaccine compliance data were obtained for employees across the entire health system from August 17, 2021, through September 13, 2021, and radiology department–specific data were extracted. Vaccine compliance data was mapped to specific radiology job titles and the five different hospital locations.ResultsA total of 6% of radiology department employees were not fully vaccine compliant by the initial deadline of September 10, 2021. MR technologists and radiology technology assistants had the highest initial rates of noncompliance of 37% and 38%, respectively. Vaccine noncompliance rates by the mandate deadline ranged from 0.5% to 7.0% at the five hospital sites. Only one hospital required a decrease in imaging hours of operation because of the vaccine mandate.ConclusionDespite initial concerns about the impact of vaccine mandate noncompliance on departmental operations, there was ultimately little effect because of improved vaccine compliance after the mandate. Understanding individual employee and locoregional differences in vaccine compliance can help leaders proactively develop mitigation strategies to manage this new challenge during the COVID-19 pandemic.  相似文献   
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号